EQL Pharma out-license Mellozzan to a leading French Company in ADHD
EQL Pharma has today entered into an exclusive out-licensing agreement with French company H.A.C. Pharma for EQL's proprietary product Mellozzan (melatonin) for France. The agreement is in practice without a set time limit and applies to tablets in six different strengths as well as an oral solution, where the latter is newly developed and ready to be sent to authorities for registration.Mellozzan is a medicine given to children with sleep disorders who have ADHD and where sleep hygiene measures are not enough. It can also be given as a short-term treatment to adults with sleep disorders